- ICH GCP
- Registro de ensayos clínicos de EE. UU.
- Ensayo clínico NCT07223203
TRITON-PN: Un estudio para evaluar la eficacia y seguridad de Nucresiran en pacientes con amiloidosis hereditaria por transtiretina con polineuropatía (TRITON-PN)
TRITON-PN: Estudio de fase 3, global, aleatorizado y de etiqueta abierta para evaluar la eficacia y seguridad de Nucresiran en pacientes con amiloidosis mediada por transtirretina hereditaria con polineuropatía (hATTR-PN)
The purpose of this study is to:
- Determine the efficacy of nucresiran in patients with hATTR-PN by evaluating the effect on neurologic impairment, quality of life, nutritional status, disability, and gait speed
- Demonstrate superiority of nucresiran compared to in-study vutrisiran with respect to serum transthyretin (TTR) levels
Descripción general del estudio
Estado
Intervención / Tratamiento
Tipo de estudio
Inscripción (Estimado)
Fase
- Fase 3
Contactos y Ubicaciones
Estudio Contacto
- Nombre: Clinical Trial Information Line
- Número de teléfono: 1-877-ALNYLAM
- Correo electrónico: clinicaltrials@alnylam.com
Copia de seguridad de contactos de estudio
- Nombre: Clinical Trial Information Line
- Número de teléfono: 1-877-256-9526
- Correo electrónico: clinicaltrials@alnylam.com
Ubicaciones de estudio
-
-
-
Berlin, Alemania, 10117
- Reclutamiento
- Clinical Trial Site
-
Heidelberg, Alemania, 69120
- Reclutamiento
- Clinical Trial Site
-
Münster, Alemania, 48149
- Reclutamiento
- Clinical Trial Site
-
-
-
-
-
Belgrano, Argentina, C1428AQK
- Reclutamiento
- Clinical Trial Site
-
Rosario, Argentina, CP2000
- Reclutamiento
- Clinical Trial Site
-
-
-
-
-
Darlinghurst, Australia, 2010
- Reclutamiento
- Clinical Trial Site
-
Woolloongabba, Australia, 4102
- Reclutamiento
- Clinical Trial Site
-
-
-
-
-
Ribeirão Preto, Brasil, 14051-140
- Reclutamiento
- Clinical Trial Site
-
Rio de Janeiro, Brasil, 22640-100
- Reclutamiento
- Clinical Trial Site
-
Rio de Janeiro, Brasil, 22775-001
- Reclutamiento
- Clinical Trial Site
-
Salvador, Brasil, 40290-000
- Reclutamiento
- Clinical Trial Site
-
São Paulo, Brasil, 04038-002
- Reclutamiento
- Clinical Trial Site
-
-
-
-
-
Vancouver, Canadá, V5Z 1M9
- Reclutamiento
- Clinical Trial Site
-
-
-
-
-
Égkomi, Chipre, 2371
- Reclutamiento
- Clinical Trial Site
-
-
-
-
-
Seoul, Corea del Sur, 06351
- Reclutamiento
- Clinical Trial Site
-
Seoul, Corea del Sur, 05030
- Reclutamiento
- Clinical Trial Site
-
-
-
-
-
Barcelona, España, 08035
- Reclutamiento
- Clinical Trial Site
-
Huelva, España, 21005
- Reclutamiento
- Clinical Trial Site
-
L'Hospitalet de Llobregat, España, 8907
- Reclutamiento
- Clinical Trial Site
-
Madrid, España, 28040
- Reclutamiento
- Clinical Trial Site
-
Palma de Mallorca, España, 07198
- Reclutamiento
- Clinical Trial Site
-
-
-
-
Colorado
-
Aurora, Colorado, Estados Unidos, 80045
- Reclutamiento
- Clinical Trial Site
-
-
Illinois
-
Chicago, Illinois, Estados Unidos, 60611
- Reclutamiento
- Clinical Trial Site
-
-
Maryland
-
Baltimore, Maryland, Estados Unidos, 21287
- Reclutamiento
- Clinical Trial Site
-
-
Massachusetts
-
Boston, Massachusetts, Estados Unidos, 02118
- Reclutamiento
- Clinical Trial Site
-
-
Minnesota
-
Rochester, Minnesota, Estados Unidos, 55905
- Reclutamiento
- Clinical Trial Site
-
-
New York
-
New York, New York, Estados Unidos, 10032
- Reclutamiento
- Clinical Trial Site
-
New York, New York, Estados Unidos, 10016
- Reclutamiento
- Clinical Trial Site
-
-
North Carolina
-
Chapel Hill, North Carolina, Estados Unidos, 27514
- Reclutamiento
- Clinical Trial Site
-
-
Tennessee
-
Nashville, Tennessee, Estados Unidos, 37232
- Reclutamiento
- Clinical Trial Site
-
-
Texas
-
Dallas, Texas, Estados Unidos, 75246
- Reclutamiento
- Clinical Trial Site
-
Houston, Texas, Estados Unidos, 77030
- Reclutamiento
- Clinical Trial Site
-
-
-
-
-
Créteil, Francia, 94000
- Reclutamiento
- Clinical Trial Site
-
Le Kremlin-Bicêtre, Francia, 94270
- Reclutamiento
- Clinical Trial Site
-
Marseille, Francia, 13005
- Reclutamiento
- Clinical Trial Site
-
-
-
-
-
Athens, Grecia, 115 28
- Reclutamiento
- Clinical Trial Site
-
Heraklion, Grecia, 715 00
- Reclutamiento
- Clinical Trial Site
-
-
-
-
-
Dublin, Irlanda, D24 NR0A
- Reclutamiento
- Clinical Trial Site
-
-
-
-
-
Florence, Italia, 50134
- Reclutamiento
- Clinical Trial Site
-
Milan, Italia, 20133
- Reclutamiento
- Clinical Trial Site
-
Padova, Italia, 35128
- Reclutamiento
- Clinical Trial Site
-
Pavia, Italia, 27100
- Reclutamiento
- Clinical Trial Site
-
Roma, Italia, 00168
- Reclutamiento
- Clinical Trial Site
-
-
-
-
-
Bunkyo C, Japón, 113-8519
- Reclutamiento
- Clinical Trial Site
-
Kumamoto, Japón, 860-8556
- Reclutamiento
- Clinical Trial Site
-
Matsumoto-shi, Japón, 390-8621
- Reclutamiento
- Clinical Trial Site
-
Suita, Japón, 565-0871
- Reclutamiento
- Clinical Trial Site
-
-
-
-
-
Kuala Lumpur, Malasia, 59100
- Reclutamiento
- Clinical Trial Site
-
-
-
-
-
Guadalajara, México, 44670
- Reclutamiento
- Clinical Trial Site
-
Tlalpan, México, 14080
- Reclutamiento
- Clinical Trial Site
-
-
-
-
-
Lisbon, Portugal, 1649-035
- Reclutamiento
- Clinical Trial Site
-
Porto, Portugal, 4099-001
- Reclutamiento
- Clinical Trial Site
-
-
-
-
-
London, Reino Unido, NW3 2QG
- Reclutamiento
- Clinical Trial Site
-
-
-
-
-
Stockholm, Suecia, 113 61
- Reclutamiento
- Clinical Trial Site
-
Umeå, Suecia, 907 37
- Reclutamiento
- Clinical Trial Site
-
-
-
-
-
Bern, Suiza, 3010
- Reclutamiento
- Clinical Trial Site
-
-
-
-
-
Taipei, Taiwán, 10002
- Reclutamiento
- Clinical Trial Site
-
Taipei, Taiwán, 112
- Reclutamiento
- Clinical Trial Site
-
Taoyuan City, Taiwán, 33305
- Reclutamiento
- Clinical Trial Site
-
-
-
-
-
Istanbul, Turquía (Türkiye), 34093
- Reclutamiento
- Clinical Trial Site
-
Izmir, Turquía (Türkiye), 35330
- Reclutamiento
- Clinical Trial Site
-
-
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Descripción
Inclusion Criteria:
- Has documented diagnosis of hATTR-PN
- Has a diagnosis of hATTR amyloidosis with polyneuropathy with a documented TTR gene variant
- Has a neuropathy impairment score (NIS) of 5 to 130 (inclusive)
- Has a Karnofsky Performance Status (KPS) of ≥60%
Exclusion Criteria:
- Has had a liver transplant or is likely, in the opinion of the Investigator, to undergo liver transplantation during the Treatment Period of the study
- Has known other (non-hATTR) forms of amyloidosis or clinical evidence of leptomeningeal amyloidosis
- Has a New York Heart Association (NYHA) heart failure classification >2
- Has alanine aminotransferase (ALT) or aspartate aminotransferase (AST) >2.5 upper limit of normal (ULN)
- Has total bilirubin >1.5 ULN
- Has estimated glomerular filtration rate (eGFR) ≤30 mL/min/1.73m^2
- Has other known causes of sensorimotor or autonomic neuropathy
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Tratamiento
- Asignación: Aleatorizado
- Modelo Intervencionista: Asignación paralela
- Enmascaramiento: Ninguno (etiqueta abierta)
Armas e Intervenciones
Grupo de participantes/brazo |
Intervención / Tratamiento |
|---|---|
|
Experimental: Nucresiran 300 mg
Patients will be administered nucresiran 300 mg subcutaneously (SC) once every 6 months (q6M) during the Treatment Period and Treatment Extension Period |
Nucresiran 300 mg administered SC q6M
Otros nombres:
|
|
Comparador activo: Vutrisiran 25 mg followed by Nucresiran 300 mg
Patients will be administered vutrisiran 25 mg SC every 3 months (q3M) during the Treatment Period followed by nucresiran 300 mg SC q6M during the Treatment Extension Period |
Nucresiran 300 mg administered SC q6M
Otros nombres:
Vutrisiran 25 mg administered SC q3M
Otros nombres:
|
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Change from Baseline in the Modified Neuropathy Impairment Score +7 (mNIS+7) Compared to the External Placebo Group from the APOLLO Study (NCT01960348) at Month 9
Periodo de tiempo: Baseline and Month 9
|
The mNIS+7 is a composite score that measures neurologic impairment which includes the following components: physical exam of lower limbs, upper limbs and cranial nerves to assess motor strength/weakness and deep tendon reflexes, electrophysiologic measurement of large nerve fiber function, sensory testing and postural blood pressure. The mNIS+7 is scored from 0 (no impairment) to 304 points (maximum impairment). A higher score indicates a worse outcome. |
Baseline and Month 9
|
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Porcentaje de Reducción en los Niveles Séricos de TTR en el Grupo Nucresiran Comparado con el Grupo Vutrisiran del Estudio hasta el Mes 9
Periodo de tiempo: Hasta el mes 9
|
Hasta el mes 9
|
|
|
Porcentaje de Reducción en los Niveles de TTR Sérico en el Grupo de Nucresiran Comparado con el Grupo de Vutrisiran del Estudio hasta el Mes 18
Periodo de tiempo: Hasta el mes 18
|
Hasta el mes 18
|
|
|
Porcentaje de Reducción de los Niveles Séricos de TTR en el Grupo Nucresiran en Comparación con el Grupo Vutrisiran del Estudio en la Semana 6
Periodo de tiempo: Semana 6
|
Semana 6
|
|
|
Change from Baseline in Norfolk Quality of Life-Diabetic Neuropathy (Norfolk QoL-DN) Total Score Compared to the External Placebo Group from the APOLLO Study (NCT01960348) at Month 9
Periodo de tiempo: Baseline and Month 9
|
The Norfolk QoL-DN is a standardized 35-item patient-rated questionnaire used to assess 5 domains: physical function, large fiber neuropathy, activities of daily living, symptoms, small fiber neuropathy, and autonomic neuropathy. The minimum and maximum values are -4 and 136, respectively. A higher score indicates a worse outcome. |
Baseline and Month 9
|
|
Change from Baseline in Modified Body Mass Index (mBMI) Compared to the External Placebo Group from the APOLLO Study (NCT01960348) at Month 9
Periodo de tiempo: Baseline and Month 9
|
The mBMI, which is a measure of nutritional status, is calculated as the product of body mass index (BMI) (weight in kilograms divided by the square of height in meters) and serum albumin (g/L) to reflect fluid balance, such as fluid accumulation or dehydration. A negative change from baseline indicates a better outcome. |
Baseline and Month 9
|
|
Change from Baseline in the mNIS+7 Compared to the External Placebo Group from the APOLLO Study (NCT01960348) at Month 18
Periodo de tiempo: Baseline and Month 18
|
The mNIS+7 is a composite score that measures neurologic impairment which includes the following components: physical exam of lower limbs, upper limbs and cranial nerves to assess motor strength/weakness and deep tendon reflexes, electrophysiologic measurement of large nerve fiber function, sensory testing and postural blood pressure. The mNIS+7 is scored from 0 (no impairment) to 304 points (maximum impairment). A higher score indicates a worse outcome. |
Baseline and Month 18
|
|
Change from Baseline in Norfolk QoL-DN Total Score Compared to the External Placebo Group from the APOLLO Study (NCT01960348) at Month 18
Periodo de tiempo: Baseline and Month 18
|
The Norfolk QoL-DN is a standardized 35-item patient-rated questionnaire used to assess 5 domains: physical function, large fiber neuropathy, activities of daily living, symptoms, small fiber neuropathy, and autonomic neuropathy. The minimum and maximum values are -4 and 136, respectively. A higher score indicates a worse outcome. |
Baseline and Month 18
|
|
Change from Baseline in mBMI Compared to the External Placebo Group from the APOLLO Study (NCT01960348) at Month 18
Periodo de tiempo: Baseline and Month 18
|
The mBMI, which is a measure of nutritional status, is calculated as the product of body mass index (BMI) (weight in kilograms divided by the square of height in meters) and serum albumin (g/L) to reflect fluid balance, such as fluid accumulation or dehydration. A negative change from baseline indicates a better outcome. |
Baseline and Month 18
|
|
Change from Baseline in Rasch-built Overall Disability Scale (R-ODS) Compared to the External Placebo Group from the APOLLO Study (NCT01960348) at Month 18
Periodo de tiempo: Baseline and Month 18
|
The R-ODS is a patient-reported measure of level of disability on a scale of 0-48, with 0 being the worst and 48 the best (no limitations); scores are based on activities of daily living and social participation. An increase in R-ODS from baseline suggests improvement in disability, and a decrease from baseline suggests worsening of disability. |
Baseline and Month 18
|
|
Change from Baseline in Timed 10-meter Walk Test (10-MWT) Compared to the External Placebo Group from the APOLLO Study (NCT01960348) at Month 18
Periodo de tiempo: Baseline and Month 18
|
The timed 10-MWT is a measure of ambulatory ability and measures the time (in seconds) that it takes a participant to walk 10 meters (gait speed). An increase in gait speed from baseline represents improvement, and a decrease from baseline represents worsening. |
Baseline and Month 18
|
Colaboradores e Investigadores
Patrocinador
Investigadores
- Director de estudio: Medical Director, Alnylam Pharmaceuticals
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio (Actual)
Finalización primaria (Estimado)
Finalización del estudio (Estimado)
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Actual)
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Palabras clave
Términos MeSH relevantes adicionales
Otros números de identificación del estudio
- ALN-TTRSC04-004
- 2025-522544-40-00 (Ctis)
Plan de datos de participantes individuales (IPD)
¿Planea compartir datos de participantes individuales (IPD)?
Descripción del plan IPD
Phase 2-4 trials:
Access to Anonymized individual participant data that support these results is made available 12 months after study completion and not less than 12 months after the product and indication have been approved in the US and/or the EU.
Access to data may be declined where there is likelihood a patient could be identified or other feasibility issue, where there is a potential conflict of interest, a planned business activities or an actual or potential competitive risk. Data will be provided contingent upon the approval of a research proposal and the execution of a data sharing agreement. Timeframes for data access may vary and can take up to 6 months or more.
Requests for access to data can be submitted via the website www.vivli.org. Questions can also be directed to datasharing@alnylam.com.
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto farmacéutico regulado por la FDA de EE. UU.
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
producto fabricado y exportado desde los EE. UU.
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .